Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 11/20 | 0.44 |
| ▸ | FNTB | P49356 | 11/20 | 0.44 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.32 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.30 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.30 |
| ▸ | TCF7L2 | Q9NQB0 | 1/20 | 0.30 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3499540 | 0.95 | FNTA (0.48) | FNTAFNTBPGGT1BCYP19A1NR1H4 | |
| SCHEMBL3682663 | 0.95 | FNTA (0.48) | FNTAFNTBPGGT1BCYP19A1NR1H4 | |
| Trifluoroacetic Acid SCHEMBL8147178 | 0.91 | FNTA (0.54) | FNTAFNTBPGGT1BCYP19A1 | |
| SCHEMBL445626 | 0.85 | FNTA (0.59) | FNTAFNTBPGGT1BCYP19A1 | |
| SCHEMBL3687066 | 0.85 | FNTA (0.59) | FNTAFNTBPGGT1BCYP19A1 | |
| SCHEMBL5553376 | 0.81 | FNTA (0.40) | FNTAFNTBPGGT1BCYP19A1 | |
| Trifluoroacetic Acid SCHEMBL8447777 | 0.81 | FNTA (0.36) | FNTAFNTBPGGT1BCYP19A1 | |
| SCHEMBL445939 | 0.80 | FNTA (0.51) | FNTAFNTBPGGT1BCYP19A1NR1H4 | |
| SCHEMBL5131468 | 0.80 | FNTA (0.51) | FNTAFNTBPGGT1BCYP19A1NR1H4 | |
| Trifluoroacetic Acid SCHEMBL8162228 | 0.79 | FNTA (0.43) | FNTAFNTBPGGT1BCYP19A1CTNNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0906099-A4 | A METHOD OF TREATING CANCER | MERCK & CO INC (US) | 2001-02-07 | — | — | EP | disclosed |
| EP-0952842-A2 | A METHOD OF TREATING CANCER | Merck & Co., Inc. (US) | 1999-11-03 | — | — | EP | disclosed |
| EP-0934270-A1 | A METHOD OF TREATING CANCER | Merck & Co., Inc. (US) | 1999-08-11 | — | — | EP | disclosed |
| EP-0906099-A1 | A METHOD OF TREATING CANCER | Merck & Co., Inc. (US) | 1999-04-07 | — | — | EP | disclosed |
| EP-0820445-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 1998-01-28 | — | — | EP | disclosed |
| WO-1997045412-A1 | A METHOD OF TREATING CANCER | MERCK & CO., INC. (US) | 1997-12-04 | — | — | WO | disclosed |
| WO-1997038664-A2 | A METHOD OF TREATING CANCER | MERCK & CO., INC. (US) | 1997-10-23 | — | — | WO | disclosed |
| WO-1997036587-A1 | A METHOD OF TREATING CANCER | MERCK & CO., INC. (US) | 1997-10-09 | — | — | WO | disclosed |
| WO-1996030343-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1996-10-03 | — | — | WO | disclosed |